undamentalytics Newsletter

Labcorp insider trading

Every open-market purchase and sale by Labcorp's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Labcorp insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Labcorp’s insiders pay?

From April 27, 2010 to August 6, 2026, 30 insiders reported 5 open-market purchases and 117 sales not made under a pre-set plan in Labcorp. Twelve months after each purchase was reported, the shares were +1.1% against the S&P 500 on average (median −1.8%), over 5 purchases with a full year of prices; 40% beat the index. After sales, the shares moved −4.8% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on July 29, 2010 into $23,286 by November 2, 2026, +5.3% a year. It held shares 22% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $23,168 (+5.3% a year), and held throughout $91,323 (+14.6%).

$0$50.0k$100k 201020122014201620182020202220242026 $91.3k$23.3k$23.2k
Copying Labcorp's insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Labcorp's insiders from July 29, 2010, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 22% of the time.
Labcorp: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Belingard Jean-Luc Director 0 — — 11 −0.5% (11) May 5, 2021
Eisenberg Glenn A Executive Vice President 0 — — 10 −5.0% (10) December 4, 2024
Eberts F Samuel III Chief Legal Officer, Secretary 0 — — 9 −9.6% (9) August 29, 2017
Wilkinson Peter J SVP, Chief Accounting Officer 0 — — 9 −6.1% (8) August 5, 2026
Mittelstaedt Robert E Jr Director 0 — — 8 −1.9% (8) February 27, 2017
Van Der Vaart Sandra D EVP, Corporate Affairs 0 — — 7 −2.8% (6) March 3, 2026
Williams R Sanders Director 0 — — 7 −3.4% (7) August 15, 2017
Anderson Kerrii B Director 0 — — 6 −7.6% (6) March 7, 2025
Lane Wendy E Director 0 — — 6 −0.2% (6) May 2, 2014
Uthgenannt Lisa J Chief Human Resources Officer 0 — — 6 −8.1% (6) September 6, 2019
Gilliland Dwight Gary Director 0 — — 5 −6.3% (5) August 1, 2025
Berberian Lance EVP, CIO & CTO 0 — — 4 −4.3% (4) August 7, 2024
Caveney Brian J EVP, Pres of ED, CMO & CSO 2 −9.0% (2) 0% 2 −16.5% (1) February 26, 2026
Kirchgraber Paul R CEO, Covance Drug Development 0 — — 4 −12.8% (4) May 23, 2023
Boyle James T. JR. EVP, Chief Operating Officer 0 — — 3 −8.0% (3) June 10, 2014
Dodson Edward T Principal Accounting Officer 0 — — 3 −8.9% (3) June 8, 2018
Hayes William B Chief Financial Officer, EVP 0 — — 3 +10.1% (3) June 10, 2014
Summy Amy B. EVP, Chief Marketing Officer 0 — — 3 −8.5% (2) August 6, 2026
Mac Mahon Thomas P Director 0 — — 2 −11.4% (2) September 10, 2012
Weikel M Keith Director 0 — — 2 −4.2% (2) May 9, 2014
Conrad Andrew J EVP, Chief Scientific Officer 1 +2.9% (1) 100% 0 — July 28, 2010
Divincenzo Jonathan P. EVP, Pres, Central Labs & Intl 0 — — 1 −2.0% (1) February 22, 2024
Gary M. Huff CEO, LabCorp Diagnostics 0 — — 1 −13.8% (1) June 1, 2018
Herring Joseph L CEO of Covance Drug Division 0 — — 1 −5.3% (1) February 27, 2015
King David P Director 0 — — 1 +20.4% (1) May 7, 2020
Neupert Peter M Director 1 −1.8% (1) 0% 0 — February 18, 2022
Parham Richelle P Director 0 — — 1 — November 4, 2025
Schechter Adam H President & CEO 0 — — 1 — March 5, 2026
Seltz Judith C EVP, CHRO 1 +22.1% (1) 100% 0 — May 4, 2020
Walton Andrew Scott EVP 0 — — 1 −5.6% (1) November 2, 2010

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Labcorp

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Labcorp in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 13 selling crowds, −3.2%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
March 31, 20263 selling−8.3%−1.8%not yet
December 31, 20244 selling+10.2%+6.6%−7.1%
August 30, 20243 selling−2.0%+7.2%+4.5%
May 31, 20243 selling+11.1%+9.5%+17.6%
June 29, 20186 selling−10.9%−22.7%−13.3%
August 31, 20175 selling−6.7%−0.2%−9.3%
March 31, 20173 selling+4.4%−2.4%+1.2%
August 31, 20163 selling−10.0%−7.0%−1.6%
May 29, 20153 selling+6.7%+3.1%+6.8%
May 30, 20145 selling−1.6%−9.2%+3.7%
May 31, 20135 selling−4.6%−9.1%−17.8%
May 31, 20123 selling−2.1%−7.7%−7.3%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Latest 12 of 13. Total returns from the month end; past patterns are not a forecast.

← Back to Labcorp · Funds · Politicians